TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7973478
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg triamcinolone hexacetonide (TA)
Study: 7973478
Drug: 330 mg
Normalized name: urea 330 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 330 mg sodium morrhuate (SM)
Study: 21354234
Drug: Danoprevir/r (100/100mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danoprevir/r (100/100mg twice daily) plus peginterferon alfa-2a (40KD)/ribavirin
Study: 21354234
Drug: Danoprevir/r (200/100mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danoprevir/r (200/100mg once daily) plus peginterferon alfa-2a (40KD)/ribavirin
Study: 21354234
Drug: Danoprevir/r (200/100mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danoprevir/r (200/100mg twice daily) plus peginterferon alfa-2a (40KD)/ribavirin
Study: 18506466
Drug: Liquid alginate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid alginate suspension (Gaviscon Advance) 10 ml four times daily after meals and at bedtime
Study: 10768064
Drug: ticarcillin/clavulanate (3.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: ticarcillin/clavulanate (3.1 g every 4 or 6 hours)
Study: 9260072
Drug: Immediate, informative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate, informative monetary consequence (MI) under moderate dose of alcohol (0.62 g/kg)
Study: 9260072
Drug: Delayed, uninformative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed, uninformative monetary consequence (M) under moderate dose of alcohol (0.62 g/kg)
Study: 9260072
Drug: No consequence
Approvals — FDA: no, EMA: no, PMDA: no
Description: No consequence (N) under moderate dose of alcohol (0.62 g/kg)
Study: 7678061
Drug: Low-dose aprotinin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose aprotinin (2 x 10(6) KIU in the cardiopulmonary bypass priming solution)
Study: 7073920
Drug: Midazolam (0.30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.30 mg kg‐1 i.v.)
Study: 31260526
Drug: Enzymes (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzymes (500 µg of protein/g straw DM)
Study: 29156903
Drug: Palliative radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Palliative radiotherapy (single 8 Gy radiation treatment)
Study: 26307050
Drug: Conventional intracytoplasmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional intracytoplasmic sperm injection (cICSI)
Study: 23810874
Drug: Intensified group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified group treated with RAS antagonists and beta-blockers
Study: 21184869
Drug: Propofol plus
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol plus fentanyl (0.25 mg/kg plus 50 μg intravenously)
Study: 21184869
Drug: Midazolam plus
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam plus fentanyl (0.05 mg/kg plus 50 μg intravenously)
Study: 20149045
Drug: Very low
Normalized name: Very low fat spread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very low dose oral contraceptives (100 microg levonorgestrel + 20 microg ethinyl estradiol)
Study: 20149045
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose oral contraceptives (150 microg desogestrel + 30 microg ethinyl estradiol)
Study: 20149045
Drug: Very low
Normalized name: Very low fat spread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very low dose oral contraceptives
Study: 20149045
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose oral contraceptives
Study: 17530986
Drug: CHO-PRO supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO-PRO supplement (6.2% carbohydrate and 1.5% protein)
Study: 17530986
Drug: CHO-PRO supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO-PRO supplement
Study: 1773716
Drug: Intranasal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal insulin (INI) 1 U/kg
Study: 28606620
Drug: Lumacaftor and
Normalized name: ivacaftor and lumacaftor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumacaftor and ivacaftor (200 mg lumacaftor and 250 mg ivacaftor every 12 hours for 24 weeks)
Study: 25809853
Drug: Low-fat spread
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat spread with added plant sterols (3 g/d)
Study: 22232847
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of digoxin
Study: 22232847
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of digoxin
Study: 10631214
Drug: Formoterol Turbuhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol Turbuhaler 24 microg metered dosage bid (delivered dosage 18 microg bid) + placebo
Study: 10631214
Drug: Formoterol 24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol 24 microg bid + bolus IV hydrocortisone, 200 mg
Study: 10631214
Drug: Formoterol 24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol 24 microg bid + bolus inhaled budesonide, 1,600 microg
Study: 9021907
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no treatment or digoxin for specific cases)
Study: 1411622
Drug: Carboplatin (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin (starting dose of 320 mg/m2)
Study: 27470232
Drug: Inhaled milrinone
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled milrinone (iMil)
Study: 22196566
Drug: 5 weekly
Normalized name: donepezil
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 weekly 30-min massages
Study: 22196566
Drug: 10 weekly
Normalized name: donepezil
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 weekly 30-min massages
Study: 20143202
Drug: Humor therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Humor therapy group (experimental group)
Study: 18056902
Drug: Amoxicillin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (500 mg 3 times per day for 7 days)
Study: 18056902
Drug: Topical Budesonide
Normalized name: budesonide Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Budesonide (200 mug in each nostril once per day for 10 days)
Study: 18056902
Drug: No Amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No Amoxicillin (placebo)
Study: 7827843
Drug: Desmopressin 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin 20 micrograms intranasal at night
Study: 30261839
Drug: Dexamethasone 0.1
Normalized name: dexamethasone 0.15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 0.1 mg/kg intravenous bolus before anesthetic induction
Study: 28684372
Drug: Total body
Normalized name: Total Body Massager Item
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total body irradiation (TBI) 1320 cGy, cyclophosphamide 120 mg/kg, and fludarabine 75 mg/m2 (TCF)
Study: 28684372
Drug: Nontrial chemotherapy-only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nontrial chemotherapy-only regimens
Study: 26678630
Drug: Perindopril/β-blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril/β-blocker
Study: 26678630
Drug: Placebo/β-blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo/β-blocker
Study: 23076845
Drug: Oxandrolone 0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxandrolone 0.03 mg/kg per day
Study: 23076845
Drug: Oxandrolone 0.06
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxandrolone 0.06 mg/kg per day
Study: 14978854
Drug: Warfarin (INR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (INR = 2-3)
Study: 1811815
Drug: Dalargin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalargin (1 mg bid)
Study: 27225607
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 2-propanol and benzalkonium chloride (group B)
Study: 22509084
Drug: Rabeprazole 10
Normalized name: RABEprazole 10 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 10 mg od
Study: 22509084
Drug: Famotidine 10
Normalized name: famotidine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 10 mg bid plus mosapride 5 mg tid
Study: 20132023
Drug: Zuspan's scheme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zuspan's scheme (1 g/h by continuous intravenous infusion)
Study: 20132023
Drug: Alternative scheme
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative scheme (2 g in bolus every two hours)
Study: 18386570
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment for cancer (chemotherapy and radiotherapy)
Study: 1960241
Drug: Plax pre-brushing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plax pre-brushing rinse, 15 ml, rinsed twice daily for 30 seconds
Study: 1960241
Drug: Placebo rinse,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo rinse, 15 ml, rinsed twice daily for 30 seconds
Study: 7346744
Drug: Indomethacin (IN)
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin (IN) 0.25 mg/kg orally for two doses, 24 hours apart
Study: 29040812
Drug: Snacks made
Approvals — FDA: no, EMA: no, PMDA: no
Description: Snacks made from buckwheat (32 g serving; 141 kcal)
Study: 29040812
Drug: Pita bread
Normalized name: Pita bread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pita bread made from buckwheat flour (50 g serving; 135 kcal)
Study: 19397753
Drug: Lactobacillus rhamnosus
Normalized name: Lactobacillus Rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus rhamnosus GG (LGG) administered for 4 weeks
Study: 19397753
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered for 4 weeks
Study: 17977469
Drug: DHA-rich fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA-rich fish oil (2, 4, or 6 g/d, 26% DHA, 6% EPA)
Study: 8944401
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg IV cocaine hydrochloride
Study: 2006595
Drug: Morphine and
Normalized name: morphine and antispasmodics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine and Lidocaine
Study: 6963328
Drug: moroxydine chloride
Normalized name: moroxydine
DrugBank: Moroxydine (DB13597)
Approvals — FDA: no, EMA: no, PMDA: no
Description: moroxydine chloride (0.04 g/kg a day)
Study: 6963328
Drug: no specific
Normalized name: Oregano specific IgE
Approvals — FDA: no, EMA: no, PMDA: no
Description: no specific treatment (control)
Study: 28485312
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of meropenem (loading dose of 0.5 g followed by 3 g/day)
Study: 28485312
Drug: Intermittent administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent administration of meropenem (initial dose of 1.5 g followed by 1 g every 8 hours)
Study: 19531697
Drug: Perioperative β-blocker
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perioperative β-blocker use
Study: 16855407
Drug: H. pylori
Normalized name: H. PYLORI AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. pylori infection assessment using C‐urea breath test and anti‐H. pylori IgG antibody titers
Study: 16855407
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of H. pylori infection
Study: 12874393
Drug: 3,4-diaminopyridine (3,4-DAP)
DrugBank: Amifampridine (DB11640)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 3,4-diaminopyridine (3,4-DAP) 20 mg
Study: 8205303
Drug: Isradipine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine (2.5 mg/day)
Study: 31228031
Drug: SHP465 mixed
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHP465 mixed amphetamine salts (MAS) 12.5-75 mg
Study: 28728038
Drug: Smoking cessation
Normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking cessation group treatment
Study: 16234990
Drug: Intra-articular lavage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular lavage with 5 l of saline
Study: 16234990
Drug: Intra-articular lavage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular lavage with 3 l of saline
Study: 10993032
Drug: Conjugated estrogens
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated estrogens plus sequential norgestrel (CEEP) (n = 31)
Study: 10993032
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment control (n = 50)
Study: 7504880
Drug: Amiodarone 200
Normalized name: amiodarone 200 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone 200 mg/day (n = 115)
Study: 7504880
Drug: Metoprolol 100
Normalized name: metoprolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 100 to 200 mg/day (n = 130)
Study: 7504880
Drug: No antiarrhythmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antiarrhythmic therapy (n = 123)
Study: 3517508
Drug: Nifedipine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (200 micrograms/L)
Study: 27307415
Drug: High-intensity atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity atorvastatin (80 mg/d before PCI and 40 mg/d thereafter for 1 year)
Study: 27307415
Drug: Moderate-intensity atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-intensity atorvastatin (20 mg/d for 1 year)
Study: 24709487
Drug: Docetaxel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (75 mg/m², IV) + Vandetanib (100 mg daily, PO)
Study: 24709487
Drug: Docetaxel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (75 mg/m², IV)
Study: 22680916
Drug: Continuous femoral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous femoral nerve analgesia (CFA), ropivacaine 25 mg bolus and 5 mg/h infusion for 24 hours after surgery.
Study: 22680916
Drug: Oral analgesics
Normalized name: ANALGESIC CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral analgesics (control group).
Study: 20228403
Drug: Valsartan (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (up to 160 mg daily)
Study: 15953083
Drug: Control site
Normalized name: SOLO SITE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control site (left leg, no treatment)
Study: 10578982
Drug: Antitubercular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antitubercular treatment
Study: 8340983
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (500 mg/d as calcium citrate malate)
Study: 3729636
Drug: Usual oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual oxygen prescriptions
Study: 26742708
Drug: (131)I‐MIBG (444
Approvals — FDA: no, EMA: no, PMDA: no
Description: (131)I‐MIBG (444 or 666 MBq/kg) plus arsenic trioxide (0.15 or 0.25 mg/m(2))
Study: 16415699
Drug: Sertraline (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (maximum dose of 200 mg/d)
Study: 2639596
Drug: FIBS preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: FIBS preparation
Study: 2639596
Drug: Typical treatment
Normalized name: Hongo Killer Treatment Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Typical treatment for uveitis
Study: 9286518
Drug: 20% sucrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% sucrose solution dripped onto enamel blocks from 0 to 8 times/day
Study: 3313776
Drug: Mesalazine (5-ASA)
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mesalazine (5-ASA) suppositories (3 x 250 mg/day)
Study: 28811158
Drug: Direct acting
Normalized name: DIRECT ACTING ANTIVIRALS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct acting antiviral therapy (DAAs)
Study: 18370982
Drug: Nebulized racemic
Normalized name: EPINEPHRINE,RACEMIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized racemic albuterol
Study: 19573482
Drug: Ziprasidone 40
Normalized name: ziprasidone 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone 40 to 160 mg/day, administered b.i.d.
Study: 16979126
Drug: Horse gram
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Horse gram lectin (Dolichos biflorus agglutinin) skin prick test (SPT) at 100 microg/mL
Study: 15219008
Drug: Oropharyngeal vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oropharyngeal vancomycin (0.5 g of a 4% gel at 6-hour intervals)
Study: 9328328
Drug: Interferon (IFN)
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon (IFN) treatment with IFN‐alpha2b (3 million units 3 times weekly for 12 months)
Study: 4913623
Drug: Maximal doses
Normalized name: Spirulina maxima preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximal doses of histamine acid phosphate
Study: 4913623
Drug: Supramaximal doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supramaximal doses of histamine acid phosphate
Study: 4913623
Drug: Maximal doses
Normalized name: Spirulina maxima preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximal doses of pentagastrin
Study: 4913623
Drug: Supramaximal doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supramaximal doses of pentagastrin
Study: 31732851
Drug: Grape juice
Normalized name: grape juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grape juice (10 ml/kg/day)
Study: 31732851
Drug: Placebo drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drink (10 ml/kg/day)
Study: 31234919
Drug: Tong‐luo Qu‐tong
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tong‐luo Qu‐tong plaster administered externally for 14 days (two courses, once daily)
Study: 31234919
Drug: Qi‐zheng Xiao‐tong
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qi‐zheng Xiao‐tong plaster administered externally for 14 days (two courses, once daily)
Study: 28081543
Drug: Irinotecan/S‐1 (IRIS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan/S‐1 (IRIS) therapy
Study: 23769807
Drug: N-acetylcysteine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine plus normal saline solution
Study: 23769807
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline solution only
Study: 23769807
Drug: Less than
Normalized name: IgA less than or equal to 50 mcg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Less than 1 L intravenous fluids
Study: 23769807
Drug: Greater than
Normalized name: immune globulin,alpha (IgA) greater than 50 mcg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Greater than 1 L intravenous fluids
Study: 19837206
Drug: Multidisciplinary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary treatment (MT) + Cognitive Behavior Therapy (CBT)
Study: 19837206
Drug: Multidisciplinary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary treatment (MT)
Study: 14699021
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated equine estrogen (CEE) 0.625 mg
Study: 14699021
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated equine estrogen (CEE) 0.3125 mg
Study: 14699021
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated equine estrogen (CEE) 0.625 mg and 0.3125 mg
Study: 9209015
Drug: Chemopreventive agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemopreventive agents (specific agents not mentioned)
Study: 8315422
Drug: Epirubicin 50
Normalized name: epiRUBicin 50 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin 50 mg/m2 on days 1 and 8 (every 3 weeks) with fluorouracil (5 FU) and cyclophosphamide 500 mg/m2 on day 1 of each course (group A)
Study: 8315422
Drug: Epirubicin administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin administered only on day 1 with fluorouracil (5 FU) and cyclophosphamide 500 mg/m2 on day 1 of each course (group B)
Study: 29343468
Drug: Onabotulinum toxin-A
Normalized name: Botulinum toxin A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Onabotulinum toxin-A (BoNT-A) injections (200 units: 60 into each masseter and 40 into each temporalis)
Study: 24714351
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg elemental iron
Study: 24714351
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg elemental iron
Study: 24714351
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg and 80 mg elemental iron
Study: 19484401
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser irradiation treatment (diode laser)
Study: 19484401
Drug: Topical fluoride
Normalized name: Carles 60 Second APF 1.23% Topical Fluoride Dental Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical fluoride treatment (protective varnish)
Study: 19001202
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens, 0.625 mg/d
Study: 19001202
Drug: Estrogen plus
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen plus medroxyprogesterone acetate, 2.5 mg/d
Study: 17033273
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg metoprolol tartrate
Study: 8229609
Drug: Oral activated
Normalized name: activated charcoal Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral activated charcoal (OAC) therapy, 8.5 +/- 0.85 gms before meals
Study: 2985395
Drug: ACTH 4-10
Normalized name: ACTH
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACTH 4-10 (single s.c. dose)
Study: 26663540
Drug: 1000 μg
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 μg Chromium picolinate (CrP) for 6 months
Study: 20473540
Drug: Sham pulsed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham pulsed electromagnetic field therapy (sham PEMF)